Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data

Esophageal cancer (EC) is the seventh most common malignancy globally. There are two main histological subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the predominant histological type of esophageal cancer worldwide and has worse prognosis than esophageal a...

Full description

Saved in:
Bibliographic Details
Published inCancer management and research Vol. 15; pp. 399 - 406
Main Authors Kim, Yuntae, Yamamoto, Shun, Kato, Ken
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2023
Dove
Dove Medical Press
Subjects
Apoptosis
Cancer
Care and treatment
Chemotherapy
Development and progression
Esophageal cancer
esophageal squamous cell carcinoma
immune checkpoint inhibitor
Metastasis
nivolumab
postoperative treatment
Prognosis
Review
Squamous cell carcinoma
Japan
esophageal squamous cell carcinoma
immune checkpoint inhibitor
nivolumab
postoperative treatment
Online AccessGet full text

Cover

More Information
Summary:Esophageal cancer (EC) is the seventh most common malignancy globally. There are two main histological subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the predominant histological type of esophageal cancer worldwide and has worse prognosis than esophageal adenocarcinoma. However, effective treatment for patients with ESCC remains limited. Moreover, the risk of recurrence remains high in patients with resectable ESCC even with perioperative multidisciplinary treatment, such as chemoradiotherapy or chemotherapy. Nivolumab, a human monoclonal immunoglobulin G4 antibody that inhibits programmed cell death protein 1, has recently been identified as a potential treatment for patients with metastatic esophageal cancer based on the results of the ATTRACTION-3 and CheckMate 648 trials. The CheckMate 577 trial showed survival benefits of postoperative nivolumab monotherapy compared with placebo in patients with resectable locally advanced esophageal cancer who did not achieve a pathological complete response after preoperative chemoradiotherapy. In this review, we discuss the data on the efficacy and safety of postoperative nivolumab and share future perspectives on immune checkpoint inhibitors as perioperative therapy for patients with locally advanced ESCC.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S390499